Data for Patient-derived procoagulant breast fibroblasts

Data for Figures in Ogunlayi et al Patient-derived procoagulant breast fibroblasts paper (2025).Cancer-associated fibroblasts (CAFs) play a key role in breast cancer progression and exhibit a procoagulant phenotype within the tumour microenvironment (TME). We hypothesised that this procoagulant phenotype correlates with a CAF-like phenotype and that fibroblasts distant from the immediate TME are less procoagulant. We also proposed that the procoagulant phenotype contributes functionally to breast cancer progression.File contains the data for the Figures in the Ogunlayi et al. paper (2025) written on this topic.Acronyms/Abbreviations: <b>CM</b>: Conditioned Media, <b>Fib</b>: Fibroblasts <b>IBC</b>: Invasive Breast Cancer, <b>Rep</b>: Replicate <b>SN</b>: Same breast Normal (Same breast as IBC), <b>TF</b>: Tissue Factor, <b>TFi</b>: Tissue Factor inhibition<b> </b>(monoclonal anti-TF antibody 10H10) <b>TF-OE</b>: Tissue Factor-Over Expressing, <b>TGFBRi</b>: TGFBR inhibitor (SB-431542).<br>Techniques Used:Figure 1- Immunocytochemistry (H-Score), Procoagulant activity assay (Clotting times), TF activity assay (TF concentration, pM).Figure 2- Western Blotting (expression normalised), ELISA (TGF beta 1 concentration), Procoagulant activity assay (Clotting times).Figure 3- Immunocytochemistry (H-Score), ELISA (TGF beta 1 concentration), Procoagulant activity assay (Clotting times), TF activity assay (TF concentration, pM).Figure 4- TF activity assay (TF concentration, pM), Scratch wound migration assay (rate).Supplementary Data- Immunocytochemistry (H-Score).<br>